Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy - 05/09/11
Abstract |
Graft-versus-host disease is a frequent complication of allogenic bone marrow transplantation. Approximately 10% of patients suffering from chronic graft-versus-host disease develop sclerodermic graft-versus-host disease of the skin, which often does not respond to conventional immunosuppressive therapy. An alternative to immunosuppressive treatment is photochemotherapy. We describe a patient with chronic sclerodermic graft-versus-host disease who did not respond to a combination therapy of cyclosporine and prednisone and later mycophenolate mofetil plus prednisone. A combination therapy of mycophenolate mofetil (2 g/day) and low-dose UVA1 therapy (single dose, 20 J/cm2, 4 times per week over 6 weeks) resulted in striking clinical improvement of sclerodermic graft-versus-host disease. (J Am Acad Dermatol 2000;42:134-6.)
Le texte complet de cet article est disponible en PDF.Plan
 | Reprints are not available from the authors. |
| 0190-9622/2000/$12.00 + 0 16/54/102502 |
Vol 42 - N° 1P1
P. 134-136 - janvier 2000 Retour au numéro
Article précédent
- Pustular tinea pedis
- J.V. Hirschmann, Gregory J. Raugi
- Lichen planus pemphigoides with IgG autoantibodies to the 180 kd bullous pemphigoid antigen (type XVII collagen)
- Sylvia Hsu, Reza F. Ghohestani, Jouni Uitto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?